Although thyroid cancer cells remain to be explored in combination with typical Bcl-2 inhibitor and Gal-3 inhibitor, targeting Gal-3 might be effective to improve the efficacy of Bcl-2 targeted therapy [36]. This evidence concerns the gene LGALS3 and thyroid gland carcinoma.